Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An adenocarcinoma that arises from the small intestine. Histologic variants include mucinous adenocarcinoma and signet ring cell carcinoma.
Biomarker and diagnostic research for small intestine adenocarcinoma has been reported in the published literature.
13 clinical trials registered, 1 recruiting. Interventions under study include drug therapy, biologic therapy, other interventions, and procedural interventions. Pipeline includes 10 PHASE2, 1 PHASE1, 1 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06234306](https://clinicaltrials.gov/study/NCT06234306) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:58 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care |
— |
Copenhagen University Hospital at Herlev |
RECRUITING |
185 publications have been identified in PubMed for small intestine adenocarcinoma. Research spans Case Report / Case Series (30%), Epidemiology / Natural History (20%), and Clinical Trial Publication (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 55 | 30% |
Disease patterns and progression | 37 | 20% |
Clinical study results | 28 | 15% |
Laboratory research | 26 | 14% |
Research summaries | 19 | 10% |
Testing and diagnosis research | 15 | 8% |
Other research | 3 | 2% |
New treatment approaches | 2 | 1% |
Anand U (2026). [PMID: 41667307](https://pubmed.ncbi.nlm.nih.gov/41667307/). *HPB (Oxford)*. [Epidemiology / Natural History]
Schafrat PJM (2026). [PMID: 42047476](https://pubmed.ncbi.nlm.nih.gov/42047476/). *Acta Oncol*. [Epidemiology / Natural History]
Lim M (2026). [PMID: 41871440](https://pubmed.ncbi.nlm.nih.gov/41871440/). *Oncologist*. [Clinical Trial Publication]
Roth GS (2026). [PMID: 41622055](https://pubmed.ncbi.nlm.nih.gov/41622055/). *Dig Liver Dis*. [Clinical Trial Publication]
Honaker EC (2026). [PMID: 42144080](https://pubmed.ncbi.nlm.nih.gov/42144080/). *Hum Pathol*. [Epidemiology / Natural History]
Jacobs E (2026). [PMID: 41147517](https://pubmed.ncbi.nlm.nih.gov/41147517/). *Am Surg*. [Epidemiology / Natural History]
Maratt JK (2026). [PMID: 41504306](https://pubmed.ncbi.nlm.nih.gov/41504306/). *Am J Gastroenterol*. [Review / Meta-Analysis]
Wang Y (2026). [PMID: 42217436](https://pubmed.ncbi.nlm.nih.gov/42217436/). *Cancer Treat Res Commun*. [Case Report / Case Series]
Ota M (2026). [PMID: 41717387](https://pubmed.ncbi.nlm.nih.gov/41717387/). *Respirology case reports*. [Case Report / Case Series]
Schouten TJ (2026). [PMID: 41662856](https://pubmed.ncbi.nlm.nih.gov/41662856/). *Lancet Gastroenterol Hepatol*. [Clinical Trial Publication]
AI-curated news mentioning small intestine adenocarcinoma
Updated Mar 16, 2026
A recent study highlights the association of anti-Hu paraneoplastic syndrome with gastrointestinal dysmotility in patients suffering from nasopharyngeal squamous cell carcinoma and small bowel adenocarcinoma. This research contributes to the understanding of paraneoplastic syndromes and their impact on gastrointestinal function.
A case report highlights the successful use of conversion surgery following pembrolizumab treatment in a patient with initially unresectable MSI-H small bowel adenocarcinoma. This analysis may provide insights into potential treatment pathways for similar cases.